Half-dose vaccination in healthy young individuals may be effective in times of vaccine shortage
About 10 million people in the United States alone - from troops returning from war to students with music blasting through headphones - are suffering from impairing noise-induced hearing loss. The rising trend is something that researchers and physicians at the University of Michigan Kresge Hearing Research Institute are hoping to reverse, with a cocktail
Full Post: Researchers test whether cocktail of vitamins and magnesium help prevent hearing loss
Individuals younger than 50 who have been previously vaccinated do not appear to have a substantially different immune response to a half-dose of influenza vaccine than to a full dose, according to a report in the December 8/22 issue of Archives of Internal Medicine.
This suggests that half-dose vaccination in healthy young individuals may be effective in times of vaccine shortage.
“Since 2002, optimum influenza vaccine delivery has been impaired as a result of supply shortages,” the authors write as background information in the article. “With the abrupt loss of half the anticipated national influenza vaccine supply in October 2004, the option of using a reduced dose for immunization of healthy, high-priority groups became a critical consideration.”
Renata J.M. Engler, M.D., of Walter Reed Army Medical Center, Washington, D.C., and colleagues conducted a randomized clinical trial involving healthy adults age 18 to 64 years. Between November and December 2004, a total of 554 adults received a full dose of trivalent inactivated influenza vaccine and 556 received a half-dose of the vaccine. All had been vaccinated within the past one to three years. Blood samples were taken before and 21 days after vaccination and tested for antibodies against influenza, and participants recorded any symptoms they experienced during this time period.
“Antibody responses to intramuscular half-dose trivalent inactivated influenza vaccine in healthy, previously immunized adults were not substantially inferior to the full-dose vaccine, particularly for ages 18 to 49 years,” the authors write. In addition, from November 2004 through March 2005, rates of medical visits for respiratory or cardiovascular reasons were no different between those vaccinated with a full dose or with a half dose. “Given the benefits of immunizing healthy working adults and caregivers, these data support the validity of a dose reduction strategy in the setting of vaccine shortages.”
“Reduced dosing could have a significant impact on the response to vaccine shortages, particularly at a local level when faced with considerable delays in vaccine supply delivery,” they continue. Because half-doses were associated with fewer side effects, reducing dosage could also make vaccination more acceptable, particularly among groups of people who experience more adverse effects.
Women of all ages had a greater response to both doses of the vaccine than men. In fact, women receiving a half-dose of vaccine had similar antibody responses to men receiving a full dose. “These findings suggest that guidelines for vaccine use during shortages should take sex as well as age into consideration,” the authors write. “As recommendations for influenza immunization expand and evidence that elderly persons (men older than 60 years) may require higher doses of vaccine for optimal responses, reduced doses in healthy, younger populations may become a valuable national strategy.”
(Arch Intern Med. 2008;168:2405-2414.
Editorial: Better Methods of Vaccine Production Needed
“The production of adequate supplies of yearly influenza vaccine is challenging for a number of reasons, including the need to anticipate new circulating strains in advance, adaptation of new variants for growth in embryonated hens’ eggs and an expanding target population,” writes Ann R. Falsey, M.D., of Rochester General Hospital, N.Y., in an accompanying editorial.
“If more antibodies are better, how much is ‘good enough’ in a time of critical vaccine shortage?” Dr. Falsey continues. “In trying to stretch vaccine supplies to protect the largest number of persons, we must use care to not waste vaccine by using low doses, which will ultimately not be protective. This study clearly shows that half-dose trivalent inactivated vaccine in young healthy women is a rational way to extend vaccine supply in times of critical shortage.”
“Although the results of this study are useful and can provide a guide to extending the vaccine supply during periods of shortage, perhaps the real message of this study is that better methods of influenza vaccine production that are less prone to problems are clearly needed,” she concludes.
(Arch Intern Med. 2008;168:2402-2403.
One fifth of the standard dose of a commonly used meningitis vaccine may be as effective as using the full dose. This new finding should allow scarce vaccine resources to be stretched further, especially during epidemics in Africa. In a study initiated by the Norwegian Institute of Public Health, together with Epicentre (the research arm
Full Post: Fractional dose of scarce meningitis vaccine may be effective in outbreak control
Vical Incorporated has announced that the company’s Vaxfectin-formulated H5N1 pandemic influenza DNA vaccines induced T-cell responses against a matching strain of influenza virus and demonstrated cross-clade antibody responses against a different strain in a Phase 1 clinical trial. The company previously reported that the vaccines had achieved potentially protective levels of antibody responses in
Full Post: Vaxfectin-formulated H5N1 pandemic influenza achieves T-cell responses and cross-clade reactivity in humans
Novavax, Inc. has announced favorable results from a Phase IIa human clinical trial of its seasonal influenza VLP (trivalent) vaccine candidate. The vaccine, which does not include an adjuvant, induced robust hemagglutination inhibition (HAI) responses, which have been shown to correlate with protection against seasonal influenza disease. The Phase IIa randomized, placebo-controlled clinical trial evaluated
Full Post: Novavax announces positive results in trial of seasonal influenza VLP (trivalent) vaccine candidate
Despite recent doubts about its effectiveness, the influenza vaccine does give valuable protection against illness, hospital admission and death caused by influenza, and people over 65 should have the flu jab this winter, say experts on bmj.com. Several prominent media articles have suggested that the flu vaccination programme for the over 65s is not worthwhile.
Full Post: Seniors should have the flu jab this winter, say experts
The National Association of County and City Health Officials (NACCHO) has announced a donation of up to one million doses of FluMist (Influenza Virus Vaccine Live, Intranasal) by MedImmune in a partnership aimed at increasing influenza awareness and vaccinations in underserved communities and populations. NACCHO will make these donated doses of vaccine available to selected state
Full Post: NACCHO to donate up to one million doses of FluMist